Aquestive Therapeutics (NASDAQ:AQST) CEO Sells $35,422.53 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) CEO Daniel Barber sold 8,257 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $4.29, for a total transaction of $35,422.53. Following the completion of the sale, the chief executive officer directly owned 660,574 shares of the company’s stock, valued at $2,833,862.46. This represents a 1.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Barber also recently made the following trade(s):

• On Tuesday, March 10th, Daniel Barber sold 180,677 shares of Aquestive Therapeutics stock. The shares were sold at an average price of $4.17, for a total transaction of $753,423.09.

Aquestive Therapeutics Price Performance

Shares of AQST traded down $0.05 during mid-day trading on Monday, reaching $4.13. The stock had a trading volume of 2,112,071 shares, compared to its average volume of 3,590,827. Aquestive Therapeutics, Inc. has a 52-week low of $2.22 and a 52-week high of $7.55. The business’s fifty day moving average is $4.16 and its 200 day moving average is $4.76. The firm has a market cap of $517.48 million, a price-to-earnings ratio of -6.76 and a beta of 1.50.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. The firm had revenue of $14.45 million during the quarter, compared to analysts’ expectations of $10.90 million. As a group, sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its position in Aquestive Therapeutics by 17.0% in the third quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after buying an additional 1,862 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Aquestive Therapeutics by 6.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after purchasing an additional 2,649 shares in the last quarter. Informed Momentum Co LLC lifted its position in shares of Aquestive Therapeutics by 1.8% during the fourth quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock worth $1,002,000 after purchasing an additional 2,721 shares in the last quarter. Sugar Maple Asset Management LLC lifted its position in shares of Aquestive Therapeutics by 5.9% during the first quarter. Sugar Maple Asset Management LLC now owns 58,060 shares of the company’s stock worth $241,000 after purchasing an additional 3,210 shares in the last quarter. Finally, Stifel Financial Corp increased its stake in shares of Aquestive Therapeutics by 0.9% during the fourth quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock worth $2,388,000 after buying an additional 3,300 shares during the period. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AQST. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Lake Street Capital set a $6.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Monday, April 20th. Finally, Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a research report on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $8.80.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.